December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Remix Therapeutics

News headline image
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Appoints Linda C. Bain to Board of Directors
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at Stifel 2025 Virtual Targeted Oncology Forum
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Announces Participation in Leerink Global Healthcare Conference
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
From Remix Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.